Atezolizumab for treating metastatic colorectal cancer after 2 therapies [ID1298]
Discontinued
Reference number: GID-TA10228
Please be advised that the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of atezolizumab for treating metastatic colorectal cancer after 2 therapies.
However, the company have advised that the Phase III IMblaze370 trial has failed to reach its primary end point in showing an improvement in overall survival compared to regorafenib and they will not be seeking regulatory approval from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its work programme.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes